Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Baird Maintains Outperform on Mersana Therapeutics, Raises Price Target to $20

Baird Maintains Outperform on Mersana Therapeutics, Raises Price Target to $20

Baird analyst Colleen Kusy maintains Mersana Therapeutics (NASDAQ:MRSN) with a Outperform and raises the price target from $18 to $20.

byBenzinga Newsdesk

August 9, 2022

1 minute read

Baird analyst Colleen Kusy maintains Mersana Therapeutics (NASDAQ:MRSN) with a Outperform and raises the price target from $18 to $20.

AMERISAFE Declares Special Dividend Of $3.50 Per Share And Regular Quarterly Dividend Of $0.34 Per Share

By Benzinga Newsdesk

October 25, 4:58 PM

AMERISAFE, Inc. (NASDAQ:AMSF), a specialty provider of workers' compensation insurance focused on high-hazard industries, today announced that its Board of Directors had declared a special cash dividend of $3.50 per

AMSF

Raymond James Downgrades Radius Global Infr to Underperform

By Benzinga Newsdesk

March 3, 6:30 AM

Raymond James analyst Ric Prentiss downgrades Radius Global Infr (NASDAQ:RADI) from Strong Buy to Underperform.

RADI

Salesforce Shares Plans To Downsize By 10%, Other Cost Cuts

By Anusuya Lahiri

January 4, 9:53 AM

Salesforce, Inc (NYSE: CRM) shared a restructuring plan to reduce operating costs, improve operating margins, and advance its ongoing commitment to profitable growth.

CRM